Exhibit 99.1


      Greatbatch Signs Definitive Agreement to Acquire Precimed

    Establishes Greatbatch as a Leading Supplier to Orthopedic OEMs

      Provides Diversification into $20 Billion Orthopedic Market

             Expands Global Presence into Europe and Asia


    CLARENCE, N.Y.--(BUSINESS WIRE)--Nov. 26, 2007--Greatbatch, Inc.
(NYSE: GB) announced today that it is has signed a definitive
agreement to acquire Precimed, a leading technology-driven supplier to
the orthopedic industry. This agreement also includes Precimed's
contract to acquire the operations of another company in the
orthopedic industry. The combined transaction will establish
Greatbatch as one of the top three suppliers to Orthopedic OEMs. This
transaction significantly diversifies Greatbatch's market presence
into the orthopedic market and establishes the company as a leading
OEM supplier to multiple market verticals, including the Cardiac
Rhythm Management, Vascular, Neurostimulation and Specialty Commercial
Power markets. Under terms of the agreement, the aggregate purchase
price will be approximately $125 million depending on closing
adjustments.

    Precimed is located in Orvin, Switzerland & Exton, PA, with
manufacturing operations throughout Switzerland & Indiana and sales
offices in Japan, Asia & the United Kingdom. Its products, including
instrumentation for hip & knee replacement, trauma and spine are sold
worldwide to leading orthopedic customers. Precimed's pending
acquisition will align them closer to their OEM customers and extend
its offerings to a broader range of orthopedic products. Precimed is
well known in the industry for outstanding quality and innovative
products in growing market segments such as minimally invasive
surgery, resurfacing, computer-aided surgery, RFID tracking and
disposable instruments. The company has a history of engineering
excellence in the design custom proprietary products and currently has
over 90 patents & pending patents.

    Thomas J. Hook, Greatbatch's President & CEO, commented, "This
acquisition supports our strategic vision to be a key global component
supplier to the medical device industry. Precimed has a breadth of
production capabilities, technology and relationships with orthopedic
OEMs that provides a key competitive differentiator in the market.
Combined with Precimed's capability to design, sell and manufacture
in-house turnkey solutions (instruments, implants and cases) enables
Greatbatch to obtain a growth platform in a large and growing
implantable market segment.

    "This transaction serves as Greatbatch's entree into the
attractive orthopedic market segment. The orthopedic market is a $20+
billion device industry growing at approximately 10 percent annually
with the outsourcing market expected to grow even faster. This
transaction provides Greatbatch with significant market, geographic
and customer diversification while expanding relationships with
existing Greatbatch customers.

    "Over the past several years, Precimed has been transformed into a
major supplier to the orthopedic market under the leadership of
Patrick Berdoz and John Ayliffe. An extremely important benefit of
this transaction is that Patrick and John have agreed to become part
of the Greatbatch Management team, bringing with them their enthusiasm
to continue growing the orthopedic business."

    Patrick Berdoz stated, "John Ayliffe and I are proud of the
organization we have established and believe that the combination with
Greatbatch will accelerate our growth in the orthopedic market.
Greatbatch is an outstanding organization that shares our passion for
technology innovation and customer service. I am looking forward to
the exciting opportunities this combination presents."

    Under the terms of the agreement, Greatbatch will acquire the
shares of Precimed, along with the assets of Precimed's pending
acquisition for approximately $125 million in cash, plus an additional
earnings-based contingent cash payment of up to approximately $10
million based on 2008 earnings performance. The company will utilize
cash on hand and availability under its revolving credit agreement to
fund these transactions. Both transactions are expected to close in
early 2008.

    Greatbatch's 2008 annual orthopedics revenues are anticipated to
be in the range of $100 to $120 million. Excluding the impact of the
acquisition related charges, such as in-process research development
and integration costs, Greatbatch expects this acquisition to be
neutral to GAAP EPS in 2008. In 2009 and thereafter, Greatbatch
anticipates the transaction will be accretive to GAAP earnings per
share.

    Forward-Looking Statements

    Some of the statements in this press release and other written and
oral statements made from time to time by the Company and its
representatives are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and section 21E
of the Securities Exchange Act of 1934, as amended, and involve a
number of risks and uncertainties. These statements can be identified
by terminology such as "may," "will," "should," "could," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue," or the negative of these terms
or other comparable terminology. These statements are based on the
Company's current expectations. The Company's actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: the Company's ability to complete on a timely basis, or at
all, the above mentioned acquisitions and the risks arising from
assumed and unknown liabilities associated with those acquisitions,
dependence upon a limited number of customers; customer ordering
patterns; product obsolescence; inability to market current or future
products; pricing pressure from customers; our ability to timely and
successfully implement our cost reduction and plant consolidation
initiatives; reliance on third party suppliers for raw materials,
products and subcomponents; fluctuating operating results; inability
to maintain high quality standards for our products; challenges to our
intellectual property rights; product liability claims; inability to
successfully consummate and integrate acquisitions; unsuccessful
expansion into new markets; competition; inability to obtain licenses
to key technology; regulatory changes or consolidation in the
healthcare industry; and other risks and uncertainties described in
the Company's Annual Report on Form 10-K and in other periodic filings
with the Securities and Exchange Commission. The Company assumes no
obligation to update forward-looking information in this press release
whether to reflect changed assumptions, the occurrence of
unanticipated events or changes in future operating results, financial
conditions or prospects, or otherwise.

    About Greatbatch, Inc.

    Greatbatch, Inc. (NYSE: GB) is a leading developer and
manufacturer of critical components used in medical devices for the
cardiac rhythm management, neurostimulation, vascular and
interventional radiology markets. Additionally, Electrochem Commercial
Power, a subsidiary of Greatbatch, is a world leader in the design and
manufacture of electrochemical cells, battery packs and wireless
sensors for demanding applications such as oil and gas exploration,
pipeline inspection, military, asset tracking, oceanography, external
medical and seismic surveying. Additional information about the
Company is available at www.greatbatch.com.


    CONTACT: Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             Treasurer and Director, Investor Relations
             tborowicz@greatbatch.com